Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
Mammogram Pain Reduced By Over-The-Counter Anesthetic Gel
http://www.medicalnewstoday.com/articles/115792.php
The simple application of a pain-relieving gel may reduce the breast discomfort some women experience during mammography exams, according to the results of a clinical trial published in the online edition of Radiology.
----------------------------------------------
** CANCER / ONCOLOGY News **
Merck Serono Receives European Approval For Broader Usage Of Erbitux In Metastatic Colorectal Cancer Including 1st-Line Treatment
http://www.medicalnewstoday.com/articles/115942.php
Merck KGaA announced today that it has been granted approval by the European Commission for Erbitux® (cetuximab), to update its license for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type mCRC (metastatic colorectal cancer) in combination with chemotherapy, and as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.
St. Louis Post-Dispatch Examines Treatment Options For Pregnant Women With Cancer
http://www.medicalnewstoday.com/articles/115882.php
<BR />The <A href="http://www.stltoday.com/stltoday/news/stories.nsf/news/sciencemedicine/story/d04a9312054ddb608625748c000e2a7b?OpenDocument" target=_new><CITE>St. Louis Post-Dispatch</CITE></A> on Sunday examined the "life-and-death" decisions pregnant women with cancer must make and the treatment options available to them.
Cancer Drug Delivery Research At Case Western Reserve University Cuts Time From Days To Hours
http://www.medicalnewstoday.com/articles/115876.php
Researchers at Case Western Reserve University have developed a technique that has the potential to deliver cancer-fighting drugs to diseased areas within hours, as opposed to the two days it currently takes for existing delivery systems.
End Of Life Physician-Patient Communication: Ensuring Final Chapter Is Enacted With The Greatest Skill And Compassion Possible
http://www.medicalnewstoday.com/articles/115855.php
Although a growing body of research supports a link between effective communication and patient, family and physician satisfaction, doctors, including oncologists and other specialists who frequently care for terminal patients, do not routinely receive training in end-of-life conversations during medical school, residency training, or after they start to practice medicine.
First Cancer Diagnostic Test Based On Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval
http://www.medicalnewstoday.com/articles/115853.php
Rosetta Genomics, Ltd. (NASDQ: ROSG) announces that the first molecular test based on Rosetta Genomics' proprietary microRNA technology, developed and validated by Columbia University Medical Center (CUMC), has been approved for clinical use by the New York State Department of Health Clinical Laboratory Evaluation Program.
Providing Worldwide Customers With A Single Source Solution For Cancer Treatment Rooms
http://www.medicalnewstoday.com/articles/115846.php
Veritas Medical Solutions, LLC has been formed to provide worldwide customers with a single source solution for cancer treatment rooms. Focused on providing innovative modular designs, products and services, the company provides all the pieces necessary for a rapid, turnkey therapy room installation.
MIMA Cancer Center First In World To Treat Soft Tissue Carcinoma With Stereotactic Body Radiotherapy Using RapidArc™ Radiotherapy Technology
http://www.medicalnewstoday.com/articles/115845.php
Doctors at Melbourne Internal Medical Associates (MIMA) Cancer Center have become the first in Florida to treat cancer using RapidArc™ radiotherapy technology from Varian Medical Systems (NYSE: VAR).
Cancer Molecular Diagnostics: On The Critical Path To Personalized Medicine
http://www.medicalnewstoday.com/articles/115820.php
The Healthcare practice at <i>Frost & Sullivan</i> is pleased to announce its 2008 Quarterly Analyst Briefing Presentation on the North American cancer molecular diagnostics market to be held on Thursday July 24, 2008 at 10:00 a.
Hospitals Vary In Number Of Lymph Nodes Examined In Patients With Gastric And Pancreatic Cancer
http://www.medicalnewstoday.com/articles/115814.php
Researchers have found differences in hospitals giving care to patientswith gastric or pancreatic cancer. The report, published in the Julyissue of <i>Archives of Surgery</i>, found that ifpatients are treated at hospitals that conduct relatively more cancersurgeries or at hospitals deemed comprehensive care centers, thepatients have more lymph nodes examined by physicians who areinvestigating the spread and prognosis of their disease.
Plants Make Vaccine For Treating Type Of Cancer, Stanford Study
http://www.medicalnewstoday.com/articles/115806.php
Plants could act as safe, speedy factories for growing antibodies for personalized treatments against a common form of cancer, according to new findings from the Stanford University School of Medicine.
Research Identifies Best Way To Discover If Cancer Has Spread
http://www.medicalnewstoday.com/articles/115801.php
For patients with head and neck cancer, accurately determining how advanced the cancer is and detecting secondary cancers usually means undergoing numerous tests - until now. New Saint Louis University research has found that the PET-CT scanner can be used as a stand-alone tool to detect secondary cancers, which occur in 5 to 10 percent of head and neck cancer patients.
Unnecessary Biopsies Reduced By Team Work, SLU Researchers Find
http://www.medicalnewstoday.com/articles/115800.php
Unnecessary biopsies could be a thing of the past for patients undergoing treatment for head and neck cancer. New Saint Louis University research found that when nuclear medicine clinicians and treating physicians work together to interpret PET-CT scan results, the accuracy dramatically improves, sparring patients unnecessary pain and suffering.
NICE Drug Reviews Terminated When Manufacturers Fail To Submit Evidence, July 2008, UK
http://www.medicalnewstoday.com/articles/115777.php
Because insufficient evidence was provided by the manufacturers, NICE is unable to recommend the use the following treatments in the NHS: -- bevacizumab in combination with paclitaxel for the first-line treatment of metastatic breast cancer-- bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with inoperable advanced, metastatic or recurrent non-small-cell lung cancer (other than predominantly squamous cell histology) -- carmustine implants as an adjunct to surgery in patients with recurrent glioblastoma multiforme (a type of brain cancer) for whom surgery is appropriate-- cetuximab for the treatment of colorectal cancer following failure of oxaliplatin-containing chemotherapyAndrew Dillon, NICE Chief Executive said: "NICE is committed to producing timely guidance to the NHS using our fast-track single technology appraisal process.
Intervention Delivered By Nurses Can Help Combat Depression In Cancer Patients
http://www.medicalnewstoday.com/articles/115759.php
A team of Scottish researchers have shown that cancer patients offered a depression care intervention - delivered by specially trained oncology nurses with no previous psychiatric experience - showed improvements in symptoms of depression compared to patients offered usual care.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
No news for this category today.
----------------------------------------------
** COLORECTAL CANCER News **
Merck Serono Receives European Approval For Broader Usage Of Erbitux In Metastatic Colorectal Cancer Including 1st-Line Treatment
http://www.medicalnewstoday.com/articles/115942.php
Merck KGaA announced today that it has been granted approval by the European Commission for Erbitux® (cetuximab), to update its license for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type mCRC (metastatic colorectal cancer) in combination with chemotherapy, and as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.
----------------------------------------------
** LUNG CANCER News **
No news for this category today.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
CTI To Meet With The FDA To Discuss Filing Of A Supplemental Biologics License Application For Zevalin(R)
http://www.medicalnewstoday.com/articles/115863.php
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that the Company has scheduled a meeting with the U.S. Food and Drug Administration (FDA) in September to discuss the possibility of filing a supplemental Biologics License Application (sBLA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma.
Plants Make Vaccine For Treating Type Of Cancer, Stanford Study
http://www.medicalnewstoday.com/articles/115806.php
Plants could act as safe, speedy factories for growing antibodies for personalized treatments against a common form of cancer, according to new findings from the Stanford University School of Medicine.
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
Visualisation Software To Aid Prostate Cancer Detection
http://www.medicalnewstoday.com/articles/115872.php
Visualisation specialists See3D, a spin off company of the University of Aberystwyth, is developing unique, sophisticated computer-generated models that will help doctors to improve the diagnosis and treatment of prostate cancer.
Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme In Prostate Cancer Models
http://www.medicalnewstoday.com/articles/115854.php
Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, announced the presentation of positive pre-clinical animal efficacy data for its pegylated-rHuPH20 enzyme (PEGPH20) at the American Association for Cancer Research (AACR) Translational Cancer Medicine meeting in Monterey, CA.
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment